Merck & Co., Inc., Rahway, N.J., USA Announces

Transcript

1. #1prepared remarks

   EX-99.1 2 tm2621496d1_ex99-1.htm EXHIBIT 99.1

2. #2prepared remarks

   Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline

3. #3prepared remarks

   Sales Growth Reflects Continued Strength in Oncology, Including Initial Uptake of KEYTRUDA QLEX, and Animal Health, Plus Contributions From Launches Such as WINREVAIR

4. #4prepared remarks

   | - | Total Worldwide Sales Were $16.6 Billion (5% Growth; 4% Growth ex-FX) |

5. #5prepared remarks

   | o | KEYTRUDA/KEYTRUDA QLEX 1 Sales Were $8.4 Billion (5% Growth; 4% Growth ex-FX); Includes KEYTRUDA QLEX Sales of $463 Million |

6. #6prepared remarks

   | o | WINREVAIR Sales Were $588 Million (75% Growth; 75% Growth ex-FX) |

7. #7prepared remarks

   | o | Animal Health Sales Were $1.8 Billion (8% Growth; 5% Growth ex-FX) |

8. #8prepared remarks

   | - | GAAP Loss per Share Was $0.54; Non-GAAP Loss per Share Was $0.13; GAAP and Non-GAAP Loss per Share Include a Charge of $2.31 per Share for the Acquisition of Terns |

9. #9prepared remarks

   | - | Received U.S. FDA Approval for LIPFENDRA (enlicitide), the First and Only Once-Daily Oral PCSK9 Inhibitor To Reduce LDL-C in Adults With Hypercholesterolemia |

10. #10prepared remarks

    | - | Announced Positive Data From TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (sac-TMT) in Certain Patients With Advanced or Recurrent Endometrial Cancer |

11. #11prepared remarks

    | - | Announced Positive Phase 3 Results From Once-Weekly Investigational Oral HIV Treatment Regimen of Islatravir and Lenacapavir, in Collaboration With Gilead |

12. #12prepared remarks

    | - | Narrows and Raises Expected Worldwide Sales Range To Be Between $66.3 Billion and $67.3 Billion |

13. #13prepared remarks

    | - | Now Expects Non-GAAP EPS To Be Between $2.66 and $2.76; Outlook Includes Charges of $2.43 per Share for the Acquisition of Terns, Comprised of a One-Time Charge of $2.31 per Share as Well as Costs of Approximately $0.12 per Share To Finance the Acquisition and Advance MK-4208 (Formerly TERN-701) |

14. #14prepared remarks

    1 Available in some markets as KEYTRUDA SC.

15. #15prepared remarks

    RAHWAY, N.J., Aug. 4, 2026 – Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2026.

16. #16prepared remarks

    “We continued to make substantial progress across our business this quarter, driven by strong execution and growing contributions from new product launches,” said Robert M. Davis, chairman and chief executive officer. “The FDA approval of LIPFENDRA is an exciting moment for our company and for patients, marking the latest milestone in our nearly 70-year legacy in cardiovascular disease. Together with key regulatory and clinical advances across oncology, HIV and immunology, this achievement reflects the strength of our pipeline and portfolio transformation as we bring forward the next wave of innovation. I am confident in the ongoing execution of our strategy as we deliver for patients and further enhance our long-term growth trajectory.”

17. #17prepared remarks

    $ in millions, except EPS amounts | | | 2026 | | | | 2025 | | | | Change | | | | Change Ex-

18. #18prepared remarks

    Sales | | $ | 16,607 | | | $ | 15,806 | | | | 5 | % | | | 4 | % |

19. #19prepared remarks

    GAAP net (loss) income 2 | | | (1,335 | ) | | | 4,427 | | | | N/M | | | | N/M | |

20. #20prepared remarks

    Non-GAAP net (loss) income that excludes certain items 2,3* | | | (330 | ) | | | 5,366 | | | | N/M | | | | N/M | |

21. #21prepared remarks

    GAAP EPS | | | (0.54 | ) | | | 1.76 | | | | N/M | | | | N/M | |

22. #22prepared remarks

    Non-GAAP EPS that excludes certain items 3* | | | (0.13 | ) | | | 2.13 | | | | N/M | | | | N/M | |

23. #23prepared remarks

    For the second quarter of 2026, Generally Accepted Accounting Principles (GAAP) loss / earnings per share (EPS) assuming dilution was a loss per share of $0.54 and non-GAAP loss per share was $0.13. Both the GAAP and non-GAAP loss per share were due to a charge for the acquisition of Terns Pharmaceuticals , Inc. ( Terns ) of $2.31 per share. Both GAAP and non-GAAP EPS in the second quarter of 2025 include a charge of $0.07 per share for an upfront payment related to a license agreement with Jiangsu Hengrui Pharmaceutical Co., Ltd. (Hengrui Pharma).

24. #24prepared remarks

    Non-GAAP EPS excludes acquisition- and divestiture-related costs and costs related to restructuring programs, as well as income and losses from investments in equity securities. Non-GAAP EPS in the second quarter of 2025 also excludes tax benefits primarily resulting from favorable audit reserve adjustments.

25. #25prepared remarks

    Year-to-date results can be found in the attached tables.

26. #26prepared remarks

    2 Net (loss) income attributable to the Company.

27. #27prepared remarks

    3 The Company is providing certain 2026 and 2025 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the Company’s results because management uses non-GAAP results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to this release.

28. #28prepared remarks

    The following table reflects sales of the Company’s top products and significant performance drivers.

29. #29prepared remarks

    $ in millions | | | 2026 | | | | 2025 | | | | Change | | | | Change Ex-

30. #30prepared remarks

    Total Sales | | $ | 16,607 | | | $ | 15,806 | | | | 5 | % | | | 4 | % | | |